- Current report filing (8-K)
April 27 2012 - 4:47PM
Edgar (US Regulatory)
United States
Securities and Exchange Commission
Washington, DC 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: April 24, 2012
GeneLink, Inc.
(Exact Name of Registrant as Specified in
its Charter)
PA
|
00-30518
|
23-2795613
|
(State or
other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification
No.)
|
8240 Exchange Dr. Suite C1, Orlando,
FL 32809
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code:
(800)
558-4363
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 4.01 CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT
On April 24, 2012, the Company engaged Hancock Askew & Co.,
LLP (
“Hancock Askew”
)
,
an independent member of the BDO Seidman, LLP Alliance network of firms, to be
the Company’s independent registered public accounting firm as approved by Audit Committee and ratified by the Board of Directors
As previously reported by GeneLink, Inc. (the “Company”),
on March 5, 2012, the Company was notified that the Public Company Audit Oversight Board (“PCAOB”) announced that it
had suspended for one year the registration of Buckno, Lisicky & Company, P.C. (“Buckno”), the Company’s
prior independent registered accountants, for failure to timely file Buckno’s own 2010 and 2011 annual reports with the PCAOB.
In light of the foregoing actions by the PCAOB, on March 5, 2012, Buckno resigned as the Company independent registered auditor
and its resignation was accepted by the Company's Audit Committee.
On March 14, 2012, the Company engaged Cross, Fernandez and
Riley, LLP (
“
CFR
”
)
,
an independent member of the BDO Seidman, LLP Alliance network of firms, to
audit the Company’s financial statements. Due to the 2011 engagement of CFR to assist management in researching the appropriate
accounting treatment for the sale of its Genewize subsidiary under the Stock Purchase Agreement with Capsalus Corp. and the related
license and distribution agreement, as discussed in the Company’s 8-K filing dated March 14, 2012, CFR is not considered
to be independent for the purposes of auditing the Company’s financial statements for 2011. The Company has engaged Hancock
Askew to audit the Company’s 2011 financial statements.
Due to the required change in independent accountants and the
requirement to have the Company's financial statements for the fiscal year ended December 31, 2010 re-audited, the Company
was unable to file its Annual Report on Form 10-K for the year ended December 31, 2011 in a timely manner. The Company expects
to file its Annual Report on Form 10-K on or before May 18, 2012.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibit Number
|
Description
|
99.1
|
Press Release dated April 27, 2012
|
Signatures
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GeneLink, Inc.
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/ Bernard L. Kasten, Jr. M.D.
|
|
|
|
Bernard L. Kasten, Jr. M.D.
|
|
|
|
Chief Executive Officer
|
|
Dated: April 27, 2012
EXHIBIT INDEX
Exhibit Number
|
Description
|
99.1
|
Press Release dated April 27, 2012
|
GeneLink (CE) (USOTC:GNLKQ)
Historical Stock Chart
From May 2024 to Jun 2024
GeneLink (CE) (USOTC:GNLKQ)
Historical Stock Chart
From Jun 2023 to Jun 2024